巨噬细胞-药物偶联物过继细胞疗法促进胶质母细胞瘤模型中的细胞毒性药物转移与免疫激活
研究开发了负载铁蛋白-药物偶联物的巨噬细胞-药物偶联物(MDC)平台,用于治疗免疫冷性实体瘤胶质母细胞瘤。MDC通过细胞接触依赖机制将载荷优先转移至胶质瘤细胞,在体外、离体患者样本和原位小鼠模型中显示疗效与良好安全性,并重编程免疫抑制微环境,诱导持久的T细胞依赖抗肿瘤免疫应答。
要点
- MDC由负载铁蛋白-单甲基澳瑞他汀E偶联物的巨噬细胞构成,可将药物优先转移至胶质瘤细胞。
- MDC在体外共培养、离体患者肿瘤样本和原位小鼠模型中显示靶向递送与疗效,全身毒性极小。
- MDC治疗重编程免疫抑制微环境,增强细胞毒性T细胞和B细胞浸润活化,减少调节性T细胞。
核心结论
- MDC疗法兼具细胞毒和免疫调节效应,是胶质母细胞瘤有前景的治疗策略,支持其进一步临床开发。
研究设计与样本
- 利用负载铁蛋白-药物偶联物的巨噬细胞构建巨噬细胞-药物偶联物(MDC)治疗平台,在体外共培养、离体胶质母细胞瘤患者肿瘤样本及原位胶质母细胞瘤小鼠模型中进行评价。
主要发现
- MDC负载铁蛋白偶联的单甲基澳瑞他汀E,通过涉及铁结合蛋白转移的机制,以细胞接触依赖方式将载荷优先从小鼠或人巨噬细胞转移至胶质瘤细胞。
- MDC therapy在体外、离体患者样本和原位小鼠模型中显示靶向递送与疗效,临床前安全性良好,表现为全身毒性极小和药物局部生物分布。
- MDC therapy直接杀伤肿瘤细胞,导致显著肿瘤消退并延长生存,同时重编程免疫抑制肿瘤微环境。
- 光谱流式细胞术免疫分析显示细胞毒性T淋巴细胞和B淋巴细胞浸润与活化增强,免疫抑制性调节性T细胞减少。
- MDC therapy诱导强效持久的T细胞依赖抗肿瘤免疫应答,免疫缺陷小鼠模型和淋巴细胞清除研究证实其必要性,该应答提供抗肿瘤再攻击保护。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of solid tumors faces substantial hurdles because of inadequate drug delivery and the immunosuppressive tumor microenvironment. To address these challenges, we developed a therapeutic platform using macrophages loaded with ferritin-drug conjugates, referred to as macrophage-drug conjugates (MDC), and applied it to glioblastoma, an immunologically cold solid tumor. MDC loaded with ferritin-conjugated monomethyl auristatin E enabled efficient, cell contact-dependent transfer of the payload by a mechanism involving transfer of iron-binding proteins, from either mouse or human macrophages preferentially into glioma cells. This targeted delivery and therapeutic efficacy was demonstrated across in vitro coculture systems, ex vivo assays using dissociated glioblastoma patient tumor samples, and in vivo using orthotopic glioblastoma mouse models, all while maintaining a favorable preclinical safety profile evidenced by minimal systemic toxicity and localized drug biodistribution. Beyond direct tumor cell killing leading to significant tumor regression and prolonged survival in these models, MDC therapy reprogrammed the immunosuppressive tumor microenvironment. Immune profiling by spectral flow cytometry revealed enhanced infiltration and activation of cytotoxic T lymphocytes and B lymphocytes while reducing immunosuppressive regulatory T cells. This culminated in a robust, durable, T cell-dependent antitumor immune response, the necessity of which was confirmed through studies in immunodeficient mouse models and by lymphocyte depletion, and which conferred protection against tumor rechallenge. The combined cytotoxic and immunomodulatory effects highlight the potential of MDC therapy as a promising strategy for glioblastoma treatment and support its further clinical development.
引用
- Sun M, Bialasek M, Mayoux M, et al. Adoptive cell therapy with macrophage-drug conjugates facilitates cytotoxic drug transfer and immune activation in glioblastoma models. Sci Transl Med. 2025. PMID: 40531966. doi:10.1126/scitranslmed.adr4058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。